Bells, you don't let the vax side of the business go: you keep it. It's just that you would own AHZ1 and AHZ2, rather than AHZ, the conglomerate.
The market has enough trouble valuing a medtech or biotech company as it is, without having to wrestle with 5+ very different subsidiaries, all at different stages of development.
It's a very weird and unnatural mix... I don't even know how it happened! Maybe some long-termer could tell me.
Did one of the bosses from long back say, "I have always had this urge to cure cancer"... Or "I just met a really clever guy who reckons he can come up with a vaccine for Herpes. I think we should give him some of our latest cap raise".. or something equally weird!!!!
Or was it the other way around: "Let's buy cardiocel as a quick and easy way to profits to self-fund our biotech aspirations?"
AHZ is 2 companies -why not split into 2?, page-9
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.83 |
Change
0.315(2.33%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $13.60 | $13.83 | $13.35 | $100.4K | 7.364K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 152 | $13.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.95 | 1150 | 2 |
View Market Depth
| Last trade - 11.04am 09/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |